AVNS

Avanos Medical, Inc. [AVNS] Stock Forecast

Q: What is Avanos Medical, Inc. stock symbol ?

Avanos Medical, Inc. is a US stock, located in Alpharetta of Ga and trading under the symbol AVNS

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

AVNS Stock Summary

EPS has been increasing for the past 3 quarters (Quarter statements)

EPS has increased from the previous quarter and is now positive. (Quarter statements)

AVNS has more than 2 years of cash runway (26 months)

Earnings are expected to fall -100% next year

Top 10 Correlated ETFs

AVNS

Top 10 Correlated Stocks

AVNS

In the News

AVNS Financial details

Company Rating

Buy

Market Cap

855.24M

Income

-61.8M

Revenue

705.7M

Book val./share

26.76

Cash/share

1.9

Dividend

Dividend %

Employees

3.77K

Optionable

Shortable

Yes

Earnings

01 May 2024

P/E

-16.18

Forward P/E

PEG

0.73

P/S

1.19

P/B

0.73

P/C

9.99

P/FCF

24.29

Quick Ratio

1.48

Current Ratio

3.07

Debt / Equity

0.15

LT Debt / Equity

0.13

EPS (TTM)

-1.32

EPS next Y

EPS next Q

EPS this Y

-223.15%

EPS next Y

EPS next 5Y

EPS last 5Y

6.74%

Revenue last 5Y

-0.71%

Revenue Q/Q

1.17%

EPS Q/Q

-390.77%

SMA20

SMA50

SMA100

-9.52%

Inst Own

80.01%

Inst Trans

0.85%

ROA

-3%

ROE

-4%

ROC

0.02%

Gross Margin

55%

Oper. Margin

Profit Margin

-7%

Payout

-407%

Shs Outstand

Shs Float

Target Price

52W Range

17.235-31.31

52W High

-38.77%

52W Low

+11.65%

RSI

Rel Volume

0.06

Avg Volume

265.06K

Volume

17.2K

Perf Week

-0.99%

Perf Month

-4.58%

Perf Quarter

6.57%

Perf Half Y

0.48%

Beta

0.964

Volatility

0.14%, 0.4%

Prev Close

1.5%

Price

18.98

Change

1.33%

AVNS Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	14.66	14.95	15.48	17.48	14.45
Net income per share	-0.96	-0.57	0.13	1.08	-1.33
Operating cash flow per share	-1.57	-0.05	1.81	1.94	0.7
Free cash flow per share	-2.63	-0.47	1.38	1.53	0.31
Cash per share	4.31	2.33	2.46	2.72	1.88
Book value per share	26.58	26.29	26.28	27.53	26.53
Tangible book value per share	5.88	6.2	6.68	4.71	4.31
Share holders equity per share	26.58	26.29	26.28	27.53	26.53
Interest debt per share	7.15	5.53	3.97	6.18	4.2
Market cap	1.6B	2.19B	1.67B	1.27B	1.05B
Enterprise value	1.72B	2.33B	1.74B	1.42B	1.17B
P/E ratio	-34.95	-80.63	264.7	25.13	-16.91
Price to sales ratio	2.3	3.07	2.24	1.55	1.55
POCF ratio	-21.53	-877.23	19.1	13.96	32.26
PFCF ratio	-12.82	-96.61	25.15	17.73	71.59
P/B Ratio	1.27	1.75	1.32	0.98	0.85
PTB ratio	1.27	1.75	1.32	0.98	0.85
EV to sales	2.47	3.26	2.33	1.73	1.73
Enterprise value over EBITDA	-142.5	-1.17K	36.64	11.57	11.84
EV to operating cash flow	-23.14	-932.15	19.89	15.64	36.01
EV to free cash flow	-13.78	-102.66	26.19	19.85	79.91
Earnings yield	-0.03	-0.01	0	0.04	-0.06
Free cash flow yield	-0.08	-0.01	0.04	0.06	0.01
Debt to equity	0.26	0.2	0.15	0.22	0.15
Debt to assets	0.18	0.15	0.12	0.16	0.11
Net debt to EBITDA	-9.93	-68.65	1.46	1.24	1.23
Current ratio	2.53	2.81	3.01	2.69	2.08
Interest coverage	-3.71	-2.96	2.7	7.4	3.49
Income quality	1.62	0.09	16.79	1.8	-3.27
Dividend Yield	0	0	0	0	0
Payout ratio	-0.12	-0.13	0.98	0.03	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0.05	0.05	0.04	0.04	0.04
Intangibles to total assets	0.55	0.57	0.59	0.6	0.61
Capex to operating cash flow	0.68	8.08	-0.24	-0.21	-0.55
Capex to revenue	-0.07	-0.03	-0.03	-0.02	-0.03
Capex to depreciation	-1.37	-0.47	-0.55	-0.4	-0.39
Stock based compensation to revenue	0.02	0.02	0.02	0.02	0.02
Graham number	24.01	18.35	8.8	25.83	28.14
ROIC	-0.02	-0.01	0.01	0.04	0.05
Return on tangible assets	-0.06	-0.04	0.01	0.07	-0.09
Graham Net	-2.8	-1.98	-0.8	-3.13	-3.86
Working capital	326M	300.9M	279.4M	314M	252.4M
Tangible asset value	280M	296.3M	321.1M	220.8M	200.7M
Net current asset value	4.1M	50.9M	87.9M	4.1M	30.9M
Invested capital	0.26	0.2	0.15	0.22	0.15
Average receivables	157.15M	165.85M	149.55M	149.55M	155.35M
Average payables	126.45M	75.3M	62M	62.15M	62.1M
Average inventory	133.65M	157.4M	159.6M	170.3M	176.75M
Days sales outstanding	85.7	85.74	64.31	74.74	77.41
Days payables outstanding	102.56	72.25	54.13	66.98	70.71
Days of inventory on hand	180.28	180.52	144.25	187.73	204.98
Receivables turnover	4.26	4.26	5.68	4.88	4.71
Payables turnover	3.56	5.05	6.74	5.45	5.16
Inventory turnover	2.02	2.02	2.53	1.94	1.78
ROE	-0.04	-0.02	0	0.04	-0.05
Capex per share	-1.06	-0.42	-0.44	-0.41	-0.38

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	4.68	4.11	3.62	3.66	3.75
Net income per share	0.36	-0.01	-1.46	-0.08	0.23
Operating cash flow per share	0.72	-0.15	-0.06	0.62	0.27
Free cash flow per share	0.62	-0.23	-0.14	0.54	0.15
Cash per share	2.75	2.05	1.75	2.29	1.9
Book value per share	27.77	27.87	26.38	26.11	26.76
Tangible book value per share	4.75	4.99	5.33	4.03	4.34
Share holders equity per share	27.77	27.87	26.38	26.11	26.76
Interest debt per share	6.09	5.56	5.5	6.65	3.98
Market cap	1.26B	1.39B	1.2B	946.3M	1.04B
Enterprise value	1.41B	1.55B	1.37B	1.15B	1.16B
P/E ratio	18.61	-692.94	-4.39	-63.94	24.67
Price to sales ratio	5.79	7.23	7.06	5.52	5.98
POCF ratio	37.34	-203.81	-460.08	32.52	81.6
PFCF ratio	43.69	-128.32	-181.24	37.55	152.39
P/B Ratio	0.97	1.07	0.97	0.77	0.84
PTB ratio	0.97	1.07	0.97	0.77	0.84
EV to sales	6.49	8.06	8.08	6.69	6.68
Enterprise value over EBITDA	35	101.68	138.21	87.47	34.35
EV to operating cash flow	41.86	-227.29	-526.27	39.38	91.15
EV to free cash flow	48.98	-143.11	-207.32	45.47	170.25
Earnings yield	0.01	0	-0.06	0	0.01
Free cash flow yield	0.02	-0.01	-0.01	0.03	0.01
Debt to equity	0.22	0.2	0.21	0.25	0.15
Debt to assets	0.16	0.15	0.15	0.18	0.11
Net debt to EBITDA	3.78	10.51	17.38	15.24	3.6
Current ratio	2.69	2.86	3.16	3.07	2.08
Interest coverage	8.73	0.74	-0.6	0.26	6.73
Income quality	1.99	13.6	0.04	-7.86	1.15
Dividend Yield	0.18	0	0	0.06	0
Payout ratio	13.36	-1.2	0	-15.11	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0.03	0.04	0.04	0.04	0.04
Intangibles to total assets	0.6	0.61	0.59	0.6	0.61
Capex to operating cash flow	-0.15	0.59	1.54	-0.13	-0.46
Capex to revenue	-0.02	-0.02	-0.02	-0.02	-0.03
Capex to depreciation	-0.37	-0.33	-0.35	-0.35	-0.51
Stock based compensation to revenue	0.02	0.02	0.02	0.02	0.02
Graham number	15.07	2.59	29.39	6.82	11.7
ROIC	0.01	0	0	0	0.02
Return on tangible assets	0.02	0	-0.1	-0.01	0.02
Graham Net	-3.16	-2.86	-3.46	-4.46	-3.89
Working capital	314M	295.3M	346.4M	353.9M	252.4M
Tangible asset value	220.8M	232.5M	249.6M	188.4M	200.7M
Net current asset value	4.1M	17.6M	75M	21.8M	30.9M
Invested capital	0.22	0.2	0.21	0.25	0.15
Average receivables	157.05M	155.3M	147.5M	148.75M	144M
Average payables	65.3M	63.75M	62.5M	58.75M	54.2M
Average inventory	191.95M	195.15M	174.15M	152.45M	159.9M
Days sales outstanding	69.48	67	80.91	76.29	74.16
Days payables outstanding	60.75	61.51	82.21	61.86	66.76
Days of inventory on hand	170.25	206.42	186.41	185.94	193.52
Receivables turnover	1.3	1.34	1.11	1.18	1.21
Payables turnover	1.48	1.46	1.09	1.45	1.35
Inventory turnover	0.53	0.44	0.48	0.48	0.47
ROE	0.01	0	-0.06	0	0.01
Capex per share	-0.11	-0.09	-0.09	-0.08	-0.13

AVNS Frequently Asked Questions

What is Avanos Medical, Inc. stock symbol ?

Avanos Medical, Inc. is a US stock , located in Alpharetta of Ga and trading under the symbol AVNS

What is Avanos Medical, Inc. stock quote today ?

Avanos Medical, Inc. stock price is $18.98 today.

Is Avanos Medical, Inc. stock public?

Yes, Avanos Medical, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 265.06K
Market Capitalization 855.24M
Employee 3.77K
CEO Mr. Joseph F. Woody
Headquarters Alpharetta,GA,US
IPO Date 2014-10-21
Website https://avanos.com

Avanos Medical, Inc., a medical technology company, focuses on delivering medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands. The company also provides a portfolio of non-opioid pain solutions, including acute pain products, such as On-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems; and interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.